Full Text
What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?

Abstract

Authors

W.V. Padula R. Conti R. Larson

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×